Literature DB >> 18468624

Restless legs syndrome as side effect of second generation antidepressants.

Klaus G Rottach1, Bernhard M Schaner, Michael H Kirch, Ari Z Zivotofsky, Lydia M Teufel, Thorsten Gallwitz, Thomas Messer.   

Abstract

Although of clinical interest, the question is still not fully answered whether antidepressants (AD) can cause or exacerbate restless legs syndrome (RLS). The literature provides contradictory information. This study addresses this problem for the class of second generation AD. In four neurological offices, all patients treated for the first time with an AD were prospectively observed with regard to the question of whether RLS occurred or pre-existing RLS worsened as a result of the medication. Because initial treatment in the participating offices is mainly executed with "modern" selective AD, the study was restricted to these drugs (fluoxetine, paroxetine, citalopram, sertraline, escitalopram, venlafaxine, duloxetine, reboxetine, and mirtazapine). In 9% of patients, RLS was recorded as a side effect related to the administration of AD. The frequency of this side effect varied among the drugs. The problem is most pronounced with mirtazapine provoking or deteriorating RLS in 28% of patients. By contrast, no case occurred during use of reboxetine. As for the other AD, the rate of newly occurred and deteriorated RLS, ranged from 5% to 10%. Typically, RLS occurred during the initial days of treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468624     DOI: 10.1016/j.jpsychires.2008.02.006

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  47 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

2.  Higher prevalence of periodic limb movements of sleep in patients with history of stroke.

Authors:  Fernando Morgadinho Santos Coelho; Hlynur Georgsson; Marc Narayansingh; Richard H Swartz; Brian J Murray
Journal:  J Clin Sleep Med       Date:  2010-10-15       Impact factor: 4.062

3.  Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study.

Authors:  Heike Benes; Wolfgang Mattern; Ines Peglau; Tillmann Dreykluft; Lars Bergmann; Corinna Hansen; Ralf Kohnen; Norbert Banik; S W Schoen; Magdolna Hornyak
Journal:  J Neurol       Date:  2010-12-28       Impact factor: 4.849

4.  Restless legs syndrome in an appalachian primary care population: prevalence, demographic and lifestyle correlates, and burden.

Authors:  Kim E Innes; Kathryn L Flack; Terry Kit Selfe; Sahiti Kandati; Parul Agarwal
Journal:  J Clin Sleep Med       Date:  2013-10-15       Impact factor: 4.062

5.  Augmented Restless Legs Syndrome with Marked Hyperkinesias and Impulsive-Compulsive Behaviors.

Authors:  Shen-Yang Lim; Pettarusp M Wadia; Melissa J Armstrong; Carlos H Schenck; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2015-12-15

Review 6.  What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia?

Authors:  Catherine McCall; W Vaughn McCall
Journal:  Curr Psychiatry Rep       Date:  2012-10       Impact factor: 5.285

7.  Ethnic differences in the prevalence and predictors of restless legs syndrome between Hispanics of Mexican descent and non-Hispanic Whites in San Diego county: a population-based study.

Authors:  Kittisak Sawanyawisuth; Lawrence A Palinkas; Sonia Ancoli-Israel; Joel E Dimsdale; José S Loredo
Journal:  J Clin Sleep Med       Date:  2013-01-15       Impact factor: 4.062

8.  Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management.

Authors:  Magdolna Hornyak
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

9.  Intravenous iron given prior to pregnancy for restless legs syndrome is associated with remission of symptoms.

Authors:  Daniel L Picchietti; Victor C Wang; Matthew A Picchietti
Journal:  J Clin Sleep Med       Date:  2012-10-15       Impact factor: 4.062

10.  Resolution of pregabalin and mirtazapine associated restless legs syndrome by bupropion in a patient with major depressive disorder.

Authors:  Young-Min Park; Heon-Jeong Lee; Seung-Gul Kang; Jae-Hyuck Cho; Leen Kim
Journal:  Psychiatry Investig       Date:  2009-11-19       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.